版本:
中国

BRIEF-Biomarin announces Kuvan patent challenge settlement

April 13 Biomarin Pharmaceutical Inc

* Biomarin announces Kuvan (sapropterin dihydrochloride) patent challenge settlement

* Biomarin Pharmaceutical Inc - retains exclusive U.S. rights until October 1, 2020

* Biomarin Pharmaceutical Inc - under settlement, Biomarin will grant par a non-exclusive license to its patents related to Kuvan Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐